Search

Your search keyword '"Rocha PA"' showing total 3 results
Start Over Author "Rocha PA" Language spanish; castilian
3 results on '"Rocha PA"'

1. Desempenho de frangos de corte alimentados com rações pré-iniciais contendo diferentes níveis de proteína bruta e energia metabolizável

Author

Rocha Patrícia Tironi, Stringhini José Henrique, Andrade Maria Auxiliadora, Leandro Nadja Susana Mogyca, Andrade Michelle Lobo, and Café Marcos Barcellos

Subjects
desempenho, frango de corte, programa alimentar, ração pré-inicial, Animal culture, SF1-1100
Abstract

Este experimento foi conduzido para avaliar o desempenho e a digestibilidade do nitrogênio e da matéria seca e medidas morfométricas para pintos de corte alimentados com rações contendo diferentes níveis de proteína e energia na fase pré-inicial (1 a 7 dias de idade). O delineamento experimental utilizado no experimento de desempenho foi o inteiramente casualizado em um fatorial 2 x 3 (energia: 2.850 e 3.000 kcal/kg e proteína: 20, 23 e 26%) com quatro repetições de 14 aves cada. O ensaio de digestibilidade foi realizado durante a primeira semana, utilizando-se o método da coleta total de excretas, do 4º ao 7º dia de idade. Os resultados indicaram diferenças para o consumo de ração e conversão alimentar de 1 a 7 dias e diferenças no consumo de ração de 1 a 21 dias, mostrando que os níveis de 23 e 26% de proteína foram os que apresentaram as melhores respostas para a fase pré-inicial, nas condições deste experimento. Os níveis de energia metabolizável não influenciaram o desempenho nem os valores de digestibilidade da matéria seca e de nitrogênio.

Published
2003

2. [Autoimmune encephalitis in pediatric population].

Author

Castillo Rocha PA, Hon KLE, Mohanty M, and Torres AR

Subjects
Antibodies, Autoantibodies, Child, Humans, Receptors, N-Methyl-D-Aspartate, Young Adult, Anti-N-Methyl-D-Aspartate Receptor Encephalitis diagnosis, COVID-19, Encephalitis diagnosis, Hashimoto Disease diagnosis
Abstract

Autoimmune encephalitis can be defined as central nervous system inflammation, secondary to multiple causes, where we can possibly identify the formation of auto-antibody against neurotransmitter receptors or neuronal surface proteins. Approximately 50% of patients are seropositive; the auto-antibody against N-methyl-D-aspartate receptor (NMDAR) are the most common. In the pediatric population, the clinical presentation is characterized by movement disorders and seizures, psychiatric manifestations are more commonly found in young adults. An early intervention is associated with a better prognosis in these patients. In contrast to the seropositive group, seronegative autoimmune encephalitis is linked with less movement alterations and is related with a worse cognitive outcome. Much remains to be discovered about possible etiologies, molecular processes, detection, and interaction of yet undescribed antibodies,as well as increasing our knowledge about clinical manifestations in early disease and new diagnostic techniques that could improve the diagnosis of autoimmune encephalitis. The main goal of this document is to review the updates of the molecular field about the antibody against GluK2 and its clinical presentation in pediatric population; COVID-19 as a possible cause of autoimmune encephalitis; recognize the importance of psychiatric manifestation in early disease, especially catatonia as a marker of severity; additionally consider new imaging diagnostic method such as positron emission tomography (PET), which has shown to be more sensible than MRI (goal standard).

Published
2022

3. [Pediatric therapeutic options in autoimmune neurologic diseases].

Author

López-Benítez J, Castillo Rocha PA, Hon KLE, Mohanty M, and Torres AR

Subjects
Child, Humans, Methylprednisolone therapeutic use, Autoimmune Diseases diagnosis, Autoimmune Diseases drug therapy, Encephalomyelitis, Acute Disseminated drug therapy, Multiple Sclerosis diagnosis, Neuromyelitis Optica diagnosis
Abstract

The pediatric neuroimmunology field has made significant progress in the last decade. Now, is possible to recognize primary demyelinating diseases, paraneoplastic syndromes, inflammatory (vasculitis), and granulomatous disorders that affect the central nervous system; at the same time, it is important to exclude neurologic manifestations caused by infections, toxic agents, and metabolic problems. An early diagnosis is imperative to institute treatment as soon as possible, improving outcomes. Treatment may include both, specific drugs if the etiology has been established, as well as drugs to treat potential complications, for example anticonvulsants, anti-inflammatory drugs, transfusions, or albumin replenishment within others. The main objective of this review is to provide guidance about the therapeutic options in pediatric autoimmune neurological diseases. We review the evidence and recommendations for the use of steroids in autoimmune demyelinating diseases, acute disseminated encephalomyelitis, optic neuritis, neuromyelitis optica, multiple sclerosis, among others. We will focus on current therapies, including high doses of intravenous methylprednisolone, followed by its progressive reduction, as well as intravenous immunoglobulin or plasmapheresis as second line therapies. Early institution of these treatments can save the patient's life and decrease their risk of permanent disability.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results